Schulman IRB Selected as National IRB for Cancer MoonShot

March 23, 2016

Schulman IRB will serve as the IRB of record for all participating research sites.

Schulman IRB has been selected as the national IRB for the Cancer MoonShot 2020 program.

The Cancer Moonshot 2020 coalition was formed to accelerate next generation immunotherapy and will design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients in multiple Phase I-III trials by the year 2020. Schulman IRB will serve as the IRB of record for all participating research sites. Schulman's IRB membership includes multiple oncologists and research professionals experienced in oncology research. These experts are led by an IRB Chair with extensive oncology experience in an institutional setting.

Read the full release.